Table 1. HCC patients (n = 239) categorized by NLR, PLR and their clinical pathologic characteristics.

Clinical character		NLR			PLR
		≤2.92 (n = 135)	>2.92(n = 104)	P-value	≤128.1(n = 152)	>128(n = 87)	P-value
Age, years		49.0 ± 12.47	51.28 ± 11.33	0.34	48.82 ± 11.21	52.54 ± 13.01	0.02
Serum albumin, g/L		41.36 ± 0.38	41.49 ± 0.5	0.59	41.82 ± 0.39	40.97 ± 0.49	0.18
Tumor size, cm		5.01 ± 0.26	6.99 ± 0.36	0.00	5.18 ± 0.25	7.17 ± 0.39	0.00
Platelet 10ˆ9/L		156.0 ± 6.92	167.7 ± 6.89	0.25	133.4 ± 4.43	209.7 ± 9.03	0.00
TBil, µmol/L		14.2 ± 0.63	16.24 ± 1.52	0.18	14.56 ± 0.57	16.02 ± 1.82	0.35
ALT, U/L		41.06 ± 2.77	44.91 ± 3.19	0.36	41.66 ± 2.39	44.62 ± 3.95	0.49
AST, U/L		44.51 ± 2.72	50.18 ± 3.05	0.17	44.18 ± 2.14	52.28 ± 4.12	0.06
PT, s		13.22 ± 0.10	13.33 ± 0.10	0.57	13.38 ± 0.09	13.06 ± 0.09	0.02
Gender	Male	115	85	0.49	132	68	0.10
	Female	20	19		20	19
HBsAg	Negative	23	14	0.48	19	18	0.10
	Positive	112	90		133	69
AFP, ng/mL	≤20	50	34	0.49	45	39	0.02
	>20	85	70		107	48
Liver cirrhosis	No	33	32	0.31	41	24	0.92
	Yes	102	72		111	63
Tumor encapsulation	No	96	72	0.78	110	58	0.37
	Yes	39	32		42	29
Tumor number	Single	105	77	0.54	119	63	0.35
	Multiple	30	27		33	24
Satellite nodules	No	125	96	0.98	146	75	0.01
	Yes	10	8		6	12
Edmondson grade	I–II	103	83	0.53	116	70	0.52
	III–IV	32	21		36	17
BCLC stage	0	11	0	0.00	10	1	0.04
	A	93	60		101	52
	B	28	17		27	18
	C	3	27		14	16
TNM stage	I	95	48	0.00	102	41	0.01
	II	30	19		27	22
	III	10	37		23	24

Notes.

Characteristics.

NLR

neutrophil-to-lymphocyte ratio

HBsAg

hepatitis B surface antigen

AFP

α-fetoprotein

TNM

tumor-node-metastasis

TBil

total bilirubin

PT

prothrombin time

CTP

Child-Turcotte-Pugh

BCLC stage

The Barcelona Clinic Liver Cancer staging

ALT

glutamic-pyruvic transaminase

AST

glutamic oxalacetic transaminase